Search Results - "Sherwin, K"

Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy by Ji, Yan, Sy, Sherwin K. B.

“…Immuno-oncology (IO) therapies have changed the cancer treatment landscape. Immune checkpoint inhibitors (ICIs) have improved overall survival in 20–40% of…”
Get full text

Metabolomics unveil key pathways underlying the synergistic activities of aztreonam and avibactam against multidrug-resistant Escherichia coli by Zhou, Xuefeng, Zhang, Jiayuan, Chen, Jianqi, Wang, Li, Yu, Mingming, Sy, Sherwin K. B., Yang, Hai

“…Purpose Aztreonam/avibactam is effective against serious infections caused by Gram-negative bacteria including Enterobacterales harboring metallo-β-lactamases…”
Get full text

Evaluating the status of antibiotic approvals and readiness to combat antimicrobial resistance: What else can we do better? by Oo, Charles, Zhang, Xiaoping, Sy, Sherwin K.B.

“…•Antimicrobial resistance (AMR) poses a global threat, primarily caused by bacteria. In 2019, AMR claimed the lives of 1.27 million people worldwide,…”
Get full text

Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease by Sy, Sherwin K. B., Tanaka, Chiaki, Grosch, Kai

“…Background and objectives Crizanlizumab is a humanized monoclonal antibody against P-selectin for the prevention of vaso-occlusive crises in sickle cell…”
Get full text

Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development by Sy, Sherwin K. B., Zhuang, Luning, Sy, Serubbabel, Derendorf, Hartmut

“…Avibactam is a non-β-lactam, β-lactamase inhibitor of the diazabicyclooctane class that covalently acylates its β-lactamase targets, encompassing extended…”
Get full text

Simultaneous Determination of Levo-tetrahydropalmatine and Naltrexone in Rat Plasma by LC-MS/MS and its Application in a Pharmacokinetic Study by Feng, Kun, Sy, Sherwin K B, Yu, Mingming, Lv, Zhihua, Yan, Meixing

“…Levo-tetrahydropalmatine and low-dose naltrexone are used in association with reducing cocaine-related cravings, but there are no analytical methods for the…”
Get more information

Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae by Albiero, James, Sy, Sherwin K B, Mazucheli, Josmar, Caparroz-Assef, Silvana Martins, Costa, Bruno Buranello, Alves, Janio Leal Borges, Gales, Ana Cristina, Tognim, Maria Cristina Bronharo

“…KPC-producing Klebsiella pneumoniae causes serious infections associated with high death rates worldwide. Combination therapy consisting of fosfomycin and a…”
Get full text

Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspective by Oo, Charles, Sy, Sherwin K.B.

Get full text

Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase by Albiero, James, Mazucheli, Josmar, Barros, Juliana Pimenta Dos Reis, Szczerepa, Marcia Maria Dos Anjos, Nishiyama, Sheila Alexandra Belini, Carrara-Marroni, Floristher Elaine, Sy, Serubbabel, Fidler, Matthew, Sy, Sherwin K B, Tognim, Maria Cristina Bronharo

“…Fosfomycin combined with other antimicrobials has shown good efficacy against multidrug-resistant (MDR) bacteria in both and clinical studies; however, the…”
Get full text

Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling by Zhu, Shixing, Zhang, Jiayuan, Lv, Zhihua, Zhu, Peijuan, Oo, Charles, Yu, Mingming, Sy, Sherwin K. B.

“…Background The combination of polymyxins, meropenem, and sulbactam demonstrated efficacy against multi-drug-resistant bacillus Acinetobacter baumannii . These…”
Get full text

Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases by Li, Ying Fei, Combes, Francois Pierre, Hoch, Matthias, Lorenzo, Sebastien, Sy, Sherwin K. B., Ho, Yu-Yun

“…Background Asciminib, a first-in-class, highly potent and specific ABL/BCR-ABL1 inhibitor, has shown superior efficacy compared to bosutinib in patients with…”
Get full text

Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation by Combes, Francois Pierre, Sy, Sherwin K. B., Li, Ying Fei, Lorenzo, Sebastien, Dasgupta, Kohinoor, Kapoor, Shruti, Hoch, Matthias, Ho, Yu-Yun

“…Background and Objective Asciminib is approved in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) treated…”
Get full text

Exposure–Efficacy Analysis of Asciminib in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase by Combes, François Pierre, Li, Ying Fei, Hoch, Matthias, Lorenzo, Sebastien, Ho, Yu‐Yun, Sy, Sherwin K. B.

“…Asciminib (Scemblix) is a first‐in‐class BCR::ABL1 inhibitor that works by specifically targeting the ABL myristoyl pocket (STAMP) and has potent activity…”
Get full text

Pharmacokinetics and pharmacodynamics in antibiotic dose optimization by Sy, Sherwin K B, Zhuang, Luning, Derendorf, Hartmut

“…Identifying the optimized dosing regimen and algorithm is critical in the development of antibiotics. Suboptimal regimens and inappropriate choice of drug give…”
Get more information

Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations by Martins, Frederico Severino, Martins, José Eduardo Severino, Severino, Patricia, Annaert, Pieter, Sy, Sherwin K. B.

“…Aims The combination of daptomycin and ceftaroline used as salvage therapy is associated with higher survival and decreased clinical failure in complicated…”
Get full text

Physiologically based pharmacokinetic‐pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics by Martins, Frederico S., Zhu, Peijuan, Heinrichs, M. Tobias, Sy, Sherwin K. B.

“…Aims The objective of the current study was to evaluate paediatric dosing regimens for meropenem plus fosfomycin that generate sufficient coverage against…”
Get full text

Metabolomics revealed mechanism for the synergistic effect of sulbactam, polymyxin-B and amikacin combination against Acinetobacter baumannii by Zhu, Shixing, Yue, Jiali, Wang, Xintong, Zhang, Jiayuan, Yu, Mingming, Zhan, Yuanchao, Zhu, Yuanqi, Sy, Sherwin K B, Lv, Zhihua

“…The emergence of multidrug-resistant (MDR) prompts clinicians to consider treating these infections with polymyxin combination. Metabolomic analysis was…”
Get full text

Clinical Pharmacology of Asciminib: A Review by Hoch, Matthias, Huth, Felix, Manley, Paul William, Loisios-Konstantinidis, Ioannis, Combes, Francois Pierre, Li, Ying Fei, Fu, Yunlin, Sy, Sherwin K. B., Obourn, Vanessa, Chakraborty, Abhijit, Hourcade-Potelleret, Florence

“…Asciminib is a first-in-class allosteric inhibitor of the kinase activity of BCR::ABL1, specifically targeting the ABL myristoyl pocket (STAMP). This review…”
Get full text

Fixed-dose combinations: a potential means to boost drug development for selected drugs by Oo, Charles, Sy, Sherwin K.B.

Get full text

Prediction of tissue exposures of polymyxin-B, amikacin and sulbactam using physiologically-based pharmacokinetic modeling by Wu, Mengyuan, Feng, Kun, Wu, Xiao, Liu, Chang, Zhu, Shixing, Martins, Frederico S, Yu, Mingming, Lv, Zhihua, Yan, Meixing, Sy, Sherwin K B

“…The combination antimicrobial therapy consisting of amikacin, polymyxin-B, and sulbactam demonstrated synergy against multi-drug resistant . The objectives…”
Get full text